Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Hydroxychloroquine was granted FDA approval on 18 April 1955.
A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 200
- Registration Number
- NCT05247554
Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 70
- Registration Number
- NCT05237843
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
- Conditions
- Tumor, SolidGastrointestinal Cancer
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 47
- Registration Number
- NCT05221320
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Hydroxychloroquine in Mild Graves' Orbitopathy
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 108
- Registration Number
- NCT05126147
- Locations
- 🇨🇳
National Taiwan University Hospital, Hsin-Chu branch, Hsinchu, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis
- Conditions
- Ulcerative Colitis (Disorder)
- Interventions
- First Posted Date
- 2021-11-12
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 3
- Registration Number
- NCT05119140
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital, New York, New York, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
The Potential Use of Nebulized Hydroxychloroquine for the Treatment of COVID-19
- Conditions
- 2019 Novel Coronavirus
- Interventions
- Other: standard of care (SOC) for COVID-19
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Ministry of Health Jordan
- Target Recruit Count
- 110
- Registration Number
- NCT05113810
- Locations
- 🇯🇴
Prince Hamza Hospital/ Amman Field Hospital, Amman, Jordan
New Clinical End-points in Patients With Primary Sjögren's Syndrome
- Conditions
- Primary Sjögren's Syndrome (pSS)
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 300
- Registration Number
- NCT05113004
- Locations
- 🇫🇷
Eric Hachulla, Lille, France
🇫🇷Raphaele Seror, Le Kremlin-Bicêtre, Ile De France, France
🇫🇷Jacques Morel, Montpellier, France
The Danish Pre-HCQ COVID Dialysis Study
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Nicholas Carlson
- Registration Number
- NCT05110651
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇰Herlev Hospital, Herlev, Denmark
🇩🇰North Zealand Hospital, Hillerød, Denmark
Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 30
- Registration Number
- NCT05084872
- Locations
- 🇫🇷
Larrey Hospital - Toulouse University Hospital, Toulouse, France
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
- Conditions
- COVID-19
- Interventions
- Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™)Drug: Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)Other: No treatmentDrug: Monoclonal antibodiesDrug: Molnupiravir
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 3800
- Registration Number
- NCT05041907
- Locations
- 🇳🇵
Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal
🇧🇷Universidade Federal de Minas Gerais, Minas Gerais, Brazil
🇱🇦Laos-Oxford-Mahosot Wellcome Trust Research Unit, Vientiane, Lao People's Democratic Republic
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.